Ondine Biomedical (LON:OBI) Stock Price Down 2.4% – Time to Sell?

Ondine Biomedical Inc. (LON:OBI) was down 2.4% on Monday . The stock traded as low as C$10.00 and last traded at C$10.25. Approximately 198,421 shares were traded during mid-day trading, a decline of 23% from the average daily volume of 257,823 shares. The stock had previously closed at C$10.50.

Ondine Biomedical Price Performance

The stock has a market cap of C$5.72 billion, a price-to-earnings ratio of -1.57 and a beta of 0.32. The company has a quick ratio of 8.26, a current ratio of 0.97 and a debt-to-equity ratio of 76.45. The business’s fifty day moving average is C$9.07 and its two-hundred day moving average is C$11.42.

About Ondine Biomedical

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings. We are focused on solutions that address significant needs, are easy to deploy, are environmentally safe, provide substantial public health benefits, and cost a fraction of the infections they target.

Our photodisinfection technology has been used successfully for many years in more than 100,000 patient treatments in hospitals, clinics, and industrial settings across Canada.